This Phase I Clinical trial will test the safety, tolerability and pharmacokinetics of Bod’s proprietary Ecs315 extract presented as a sublingual wafer. A positive trial outcome will leave the Company with a unique, patent protected, standardised and reproducible cannabis product which maybe sold or licenced to major pharmaceutical companies.Perhaps following this trial there should be a 'proof of concept' Phase 1b for a specific condition, possibly targeting the autism spectrum (?) and possibly leading to an IND application with the FDA (?).
- Forums
- ASX - By Stock
- BOD
- Ann: Trial ready Cannabis Sublingual Wafer Formulation complete
Ann: Trial ready Cannabis Sublingual Wafer Formulation complete, page-2
-
- There are more pages in this discussion • 18 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add BOD (ASX) to my watchlist
|
|||||
Last
2.4¢ |
Change
0.000(0.00%) |
Mkt cap ! $4.256M |
Open | High | Low | Value | Volume |
0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Featured News
BOD (ASX) Chart |
Day chart unavailable